Volume 19, Number 7—July 2013
Research
Pneumococcal Serotypes before and after Introduction of Conjugate Vaccines, United States, 1999–20111
, Kristopher P. Heilmann, Cassie L. Dohrn, Fathollah Riahi, Daniel J. Diekema, and Gary V. Doern
Table 2
Serotype distribution of Streptococcus pneumoniae isolates, United States, 1999–2011*
| All age groups |
Children ≤5 y of age |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Before PCV7, 1999–2000 | Post-PCV7, 2004–2005 | Post-PCV7, 2008–2009 | Post-PCV13, 2010–2011 | Before PCV7, 1999–2000 | Post-PCV7, 2004–2005 | Post-PCV7, 2008–2009 | Post-PCV13, 2010–2011 | ||
| PCV7 | |||||||||
| 4† | 69 (4.6) | 34 (2.1) | 7 (0.4) | 6 (0.3) | 14 (3.1) | 0 | 0 | 0 | |
| 6B† | 157 (10.4) | 32 (1.9) | 8 (0.4) | 11 (0.6) | 73 (16.3) | 7 (2.1) | 0 | 0 | |
| 9V† | 77 (5.1) | 21 (1.3) | 5 (0.3) | 1 (0.1) | 19 (4.2) | 3 (0.9) | 0 | 0 | |
| 14† | 151 (10.0) | 13 (0.8) | 7 (0.4) | 1 (0.1) | 67 (15.0) | 0 | 1 (0.2) | 0 | |
| 18C† | 51 (3.4) | 10 (0.6) | 2 (0.1) | 3 (0.2) | 23 (5.2) | 0 | 0 | 0 | |
| 19F† | 181 (12.0) | 116 (7.0) | 61 (3.1) | 47 (2.7) | 69 (15.4) | 26 (7.9) | 15 (3.6) | 7 (1.9) | |
| 23F† | 135 (9.0) | 40 (2.4) | 5 (0.3) | 3 (0.2) | 45 (10.1) | 8 (2.4) | 2 (0.5) | 0 | |
| Total |
821 (54.5) |
266 (16.1) |
95 (4.9) |
72 (4.1) |
310 (70.1) |
44 (13.4) |
18 (4.3) |
7 (1.9) |
|
| Additional serotypes in PCV13 | |||||||||
| 1† | 17 (1.1) | 12 (0.7) | 10 (0.5) | 2 (0.1) | 3 (0.7) | 2 (0.6) | 1 (0.2) | 0 | |
| 3† | 127 (8.4) | 184 (11.2) | 165 (8.5) | 163 (9.3) | 14 (3.1) | 23 (7.0) | 17 (4.1) | 15 (4.1) | |
| 5† | 0 | 2 (0.1) | 1 (0.1) | 1 (0.1) | 0 | 0 | 1 (0.2) | 0 | |
| 6A | 87 (5.8) | 78 (4.7) | 26 (1.3) | 7 (0.4) | 35 (7.8) | 19 (5.8) | 5 (1.2) | 1 (0.3) | |
| 7F† | 21 (1.4) | 29 (1.8) | 113 (5.8) | 86 (4.9) | 2 (0.5) | 2 (0.6) | 14 (3.4) | 4 (1.1) | |
| 19A† | 33 (2.2) | 239 (14.5) | 434 (22.3) | 350 (20.0) | 12 (2.7) | 83 (25.3) | 153 (36.7) | 125 (34.1) | |
| Total |
285 (18.9) |
544 (33.0) |
749 (38.5) |
609 (34.8) |
66 (14.9) |
129 (39.3) |
191 (45.8) |
145 (39.5) |
|
| PCV related | |||||||||
| 6C | 12 (0.8) | 37 (2.3) | 141 (7.3) | 148 (8.5) | 2 (0.5) | 2 (0.6) | 29 (7.0) | 32 (8.7) | |
| 9N | 19 (1.3) | 14 (0.9) | 31 (1.6) | 34 (1.9) | 4 (0.9) | 1 (0.3) | 2 (0.5) | 2 (0.5) | |
| 23A | 10 (0.7) | 47 (2.8) | 86 (4.4) | 81 (4.6) | 0 | 9 (2.7) | 18 (4.3) | 10 (2.7) | |
| 23B | 2 (0.1) | 25 (1.5) | 58 (3.0) | 44 (2.5) | 0 | 4 (1.2) | 14 (3.3) | 11 (3.0) | |
| Other | 18 (1.2)‡ | 36 (2.2)§ | 22 (1.1)¶ | 31 (1.8)# | 5 (1.1)‡ | 4 (1.2)§ | 5 (1.2)¶ | 1 (0.3)# | |
| Total |
61 (4.1) |
159 (9.7) |
338 (17.4) |
338 (19.3) |
11 (2.5) |
20 (6.1) |
68 (16.3) |
56 (15.3) |
|
| Non-PCV | |||||||||
| 11A† | 52 (3.5) | 101 (6.1) | 77 (4.0) | 82 (4.7) | 3 (0.7) | 16 (4.9) | 12 (2.9) | 14 (3.8) | |
| 12F | 17 (1.1) | 29 (1.8) | 8 (0.4) | 14 (0.8) | 1 (0.2) | 2 (0.6) | 1 (0.2) | 0 | |
| 15A | 7 (0.5) | 45 (2.7) | 78 (4.0) | 53 (3.0) | 3 (0.7) | 10 (3.0) | 16 (3.8) | 3 (0.8) | |
| 15B† | 7 (0.5) | 38 (2.3) | 39 (2.0) | 58 (3.3) | 4 (0.9) | 12 (3.7) | 14 (3.4) | 22 (6.0) | |
| 15C | 12 (0.8) | 30 (1.8) | 29 (1.5) | 43 (2.5) | 3 (0.7) | 9 (2.7) | 13 (3.1) | 17 (4.6) | |
| 16F | 17 (1.1) | 38 (2.3) | 57 (2.9) | 39 (2.2) | 0 | 5 (1.5) | 5 (1.2) | 5 (1.4) | |
| 22F† | 36 (2.4) | 77 (4.7) | 95 (4.9) | 84 (4.8) | 3 (0.7) | 14 (4.3) | 10 (2.4) | 20 (5.4) | |
| 35B | 30 (2.0) | 73 (4.4) | 78 (4.0) | 123 (7.0) | 6 (1.3) | 24 (7.3) | 20 (4.8) | 39 (10.6) | |
| Other |
113 (7.5)** |
217 (13.2)†† |
266 (13.7)‡‡ |
190 (10.9)§§ |
19 (4.3)** |
41 (12.5)†† |
45 (10.8)‡‡ |
33 (9.0)§§ |
|
| NT |
48 (3.2) |
30 (1.8) |
37 (1.9) |
45 (2.6) |
13 (2.9) |
2 (0.6) |
4 (1.0) |
6 (1.6) |
|
| Total |
339 (22.5) |
678 (41.2) |
764 (39.3) |
731 (41.8) |
55 (12.4) |
135 (41.1) |
140 (33.6) |
159 (43.3) |
|
| All | 1,506 | 1,647 | 1,946 | 1,750 | 442 | 328 | 417 | 367 | |
*PCV7, pneumococcal conjugate 7-valent vaccine; PCV13, pneumococcal conjugate 13-valent vaccine; NT, nontypeable; ch, children.
†Serotypes in 23-valent polysaccharide pneumococcal vaccine.
‡Other low prevalence serotypes (no. isolates): in 1999–2000, serotype 7C (2), 9A (8, 2 ch), 9L (2), 18F (2), 18B (4, 3 ch).
§In 2004–2005, serotype 6D (1), 7A (1), 7C (8), 9A (5, 1 ch), 9L (5), 18F (4), 18A (3, 1 ch), 18B (5, 1 ch), 19B (3, 1 ch), 19C (1).
¶In 2008–2009, serotype 7C (12, 5 ch), 9A (3), 9L (5), 19B (1), 19C (1).
#In 2010–2011, serotype 6D (1), 7B (1 ch), 7C (21), 9A (2), 9L (5), 19B (1).
**In 1999–2000, serotype 8 (7), 10A (14, 3 ch), 11B (1), 13 (8, 1 ch), 16A (1, 1 ch), 17F (2, 1 ch), 20 (3), 21 (4, 3 ch), 25A (9, 3 ch), 25F (1), 28F (1), 28A (4), 29 (3, 1 ch), 31 (13), 33F (5, 2 ch), 33A (7, 1 ch), 34 (4), 35F (18, 2 ch), 35C (1), 36 (1), 37 (1), 38 (2), 45 (2, 1 ch), 47 (1).
††In 2004–05, serotype 2 (1), 8 (7), 10F (1), 10A (23, 1 ch), 11D (1), 12B (2), 13 (5), 15F (2), 16A (2, 1 ch), 17F (11), 20 (7, 2 ch), 21 (6, 1 ch), 24F (1), 25A (3, 1 ch), 28F (2), 28A (2), 29 (8, 6 ch), 31 (36, 6 ch), 33F (16, 4 ch), 33A (6, 3 ch), 34 (11, 1 ch), 35F (34, 6 ch), 35A (15, 4 ch), 38 (12, 3 ch), 39 (1 ch), 40 (1), 48 (1 ch).
‡‡In 2008–2009, serotype 8 (13, 1 ch), 10F (1), 10A (28, 4 ch), 10B (1), 11D (1), 13 (3), 16A (1), 17F (28, 6 ch), 20 (14, 1 ch), 21 (20, 9 ch), 22A (1 ch), 25A (6, 1 ch), 28A (2), 29 (7, 2 ch), 31 (35, 2 ch), 32F (1), 33F (23, 2 ch), 33A (17, 3 ch), 33B (3, 1 ch), 34 (23, 4 ch), 35F (25, 6 ch), 35A (2), 35C (2, 1 ch), 37 (3), 38 (3), 42 (3, 1 ch).
§§In 2010–2011, serotype 8 (10), 10A (26, 5 ch), 13 (2), 17F (15, 3 ch), 20 (6), 21 (15, 9 ch), 24A (2, 1 ch), 28A (1), 29 (3), 31 (28, 2 ch), 33F (16, 3 ch), 33A (18, 3 ch), 34 (15, 2 ch), 35F (17, 4 ch), 38 (15), 45 (1 ch).
1Presented in part at the 112th General Meeting of the American Society for Microbiology Annual Meeting, June 19, 2012, San Francisco, CA, USA (abstract no. 2986).